IDF2022-1278 Pilot trial to optimize gestational weight gain and step counts in women with gestational diabetes: ACTIVE PATIENT GDM

Background Physical activity and dietary habit optimization in women with gestational diabetes mellitus (GDM) or such a history can improve both short-term [1,2] and long-term outcomes [3]. This requires strategies that are accessible, usable, and perceived as beneficial. Aim To examine uptake and engagement for the following interventions: (1) step and weight tracking through an online platform using a pedometer and weight scale, with delivery of weekly goals;(2) weekly telephone-based health coaching;and (3) a combination of these. We are assessing recruitment, completion of health coaching sessions and/or step count and weight data upload, and participant perspectives. Method Five-city pilot randomized controlled trial (Montreal, Halifax, Calgary, Winnipeg, Toronto;Canada). Women with GDM are recruited at 20-32 weeks' gestation. Data collection is through web-based questionnaire, electronic tracking of data upload, coaching session logs, chart review (gestational weight gain;blood pressure;A1C;glucose levels;offspring sex, weight, and gestational age), in-depth telephone interview (perspectives, breastfeeding status), and mailed in pedometers with concealed windows worn for 7 days (baseline and 37 weeks). Participants are randomized to one of the 3 interventions described or a control arm (resource website only). Results The trial started in August 2019 with COVID-related interruptions. By June 30, 2022, 192/225 mothers were recruited (recruitment ongoing): 27/192 (14%) withdrew, 13 are currently undergoing interventions, and 152 completed final questionnaires. An interim process analysis of the first 52 indicates that those randomized to step and weight tracking employ the pedometer and scale a mean 81.6% (SD 29.6%) and 69.0% (SD 32.0%) of the time, respectively. High proportions report step tracking (92.3%, n = 24/26) and health coach conversations (87.5% n = 21/24) as useful, with weight tracking endorsed by over half (61.5%, n = 16/26). Conclusion The findings will inform a larger scale clinical trial in terms of impacts on gestational weight gain and appropriate for size offspring status.Copyright © 2023 Elsevier B.V.

Pharm Aco Kin Etics of Remdesivir and Its Metabolites in Participants with Moderate and Severe Hepatic Impairment

BACKGROUND: Remdesivir (RDV) is an RNA polymerase inhibitor approved for treatment of COVID-19 (200 mg loading dose, 100 mg qd thereafter) in adult and pediatric patients, primarily metabolized by the high-capacity carboxylesterase 1 pathway (80% of metabolism), and by cathepsin A and CYP3A (10% each). The extensive hepatic contribution to RDV elimination and the prevalence of liver comorbidities in COVID-19 patients warranted a study in participants with hepatic impairment (HI). METHOD(S): This is a phase 1, open-label study of RDV consisting of moderate and severe HI participants and healthy matched controls (HMC) based on age (+/- 10 years), sex, and BMI (+/- 20%). Participants received a single 100 mg IV dose of RDV and remained in the clinic for 8 days. The primary endpoint was pharmacokinetic (PK) parameters of RDV and metabolites. RESULT(S): Preliminary PK and safety data from 10 moderate and 6 severe HI participants and their HMC are available. The average PK fold-change for all analytes and matrices assessed in the study are presented (Table). No serious treatment-related adverse events and no clinically significant changes in participant lab values were reported. CONCLUSION(S): The 1.52 RDV AUCinf fold increase is within expected ranges and justifies no dose adjustment in COVID-19 patients with impaired hepatic function. (Table Presented).

Critical policy drivers for Modular integrated Construction projects in Hong Kong

Given the increased importance of identifying the critical Policy Driving Forces (PDFs) to uptake Modular integrated Construction (MiC) practices in Hong Kong (HK), this study aims to identify and examine the critical PDFs associated with MiC projects in HK from the perspective of industry experts. After drawing on the plentiful relevant literature and conducting a pilot study, an expert opinion survey was conducted to gather the necessary data for this study. The collected data were analysed using relevant significance analysis and factor analysis to identify critical PDFs and appropriate groupings. The results revealed 23 critical PDFs under seven critical components in three stages of the MiC process. Regulative PDFs show the highest criticality for up-taking the MiC in the initiation and planning and design phases, while Greater Bay Area development PDFs are critical in the construction phase. The PDF related to the COVID-19 pandemic is the only critical PDF that appeared in all three stages. As the first study that explores PDFs for MiC uptake throughout all project phases, this study contributes substantially to theory and practice while better informing policymakers on how to initiate MiC-related policies to boost MiC practice in HK, where MiC is achieving greater prominence in application.

Evaluation of the lower airway microbiota in patients with severe sars-cov2

RATIONALE:Secondary infections with bacterial pathogens are thought to be responsible for poor outcomes in the 1918 Spanish and H1N1 pandemics. We postulate that poor prognosis in patients with SARS-CoV2 may be associated with uncontrollable viral replication, co-infection with a secondary pathogen, and over exuberant host immune response. We seek to evaluate whether there is an association between distinct features of the lower airway microbiota and poor clinical outcome in patients with SARS-CoV2. METHODS:We collected lower airway samples in 148 patients from NYU admitted between 3/10/2020 and 5/10/2020 with severe respiratory failure requiring mechanical ventilation and that underwent bronchoscopy for airway clearance and/or tracheostomy. Clinical outcome was defined as dead vs alive. DNA was isolated in parallel using zymoBIOMICS™ DNA/RNA Miniprep Kit (Cat: R2002) as per manufacturer's instructions. The V4 region of the 16S rRNA gene marker was sequenced using Illumina MiSeq. Sequences were analyzed using the Quantitative Insights into Microbial Ecology (QIIME version 1.9.1) pipeline. Total bacterial load was evaluated in lower airway samples using digital droplet PCR targeting the 16S rRNA gene. RESULTS:Of the 148 patients included, 114 survived (77%) and 34 (23%) died. Among those with poor clinical outcome, there was a non-statistically significant trend towards higher age and BMI. Patients who died more commonly had chronic kidney disease and prior cerebrovascular accidents, and more often required dialysis. There was no statistically significant difference in the rate of positive bacterial respiratory or blood cultures among those that survived vs. those that died (75 vs. 73% and 43 vs 38%, respectively). Topographical analysis of the 16S RNA microbiome shows compositional differences between the upper and lower airways based on β diversity comparisons. When comparing across clinical outcomes, the α diversity was lower in the dead group but there was no statistically significant difference in overall community composition (β diversity). Taxonomic differential enrichment analysis using DESeq analysis showed that oral commensals were enriched in the group that survived. Patients that died had a higher bacterial load in their lower airways than those who survived. CONCLUSION:Using samples obtained via bronchoscopy we identified lower airway microbiota signatures associated with mortality among critical patients infected with SARS-CoV2. Taxonomic signals identified as associated with poor prognosis did not reveal bacterial taxa commonly classified as respiratory pathogens. This data is not supportive of the hypothesis that secondary untreated bacterial co-infections are responsible for increased mortality in patients with severe SARS-CoV-2.

A fuzzy synthetic evaluation of vulnerabilities affecting supply chain resilience of industrialized construction in Hong Kong

Purpose Demands for Industrialized Construction (IC) have intensified with growing construction industry imperatives to (A) boost performance;(B) reduce reliance on "in-situ and on-site" operations;and (C) strengthen supply chain resilience (SCR) not just for survival but also to fulfill obligations to clients in the coronavirus disease 2019-induced (COVID-19-induced) "new normal". In addressing these imperatives, this paper targets more effective leveraging of latent efficiencies of off-site-manufacture, based on findings from a Hong Kong (HK)-based study on assessing and improving SCR in IC in a high-density city. Design/methodology/approach Starting with the identification of critical supply chain vulnerabilities (CSCVs), this study developed a multilevel-multicriteria mathematical model to evaluate the vulnerability levels of IC supply chains (SCs) in HK based on an in-depth questionnaire survey followed by experts' inputs and analyzing them using fuzzy synthetic evaluation (FSE). Findings The overall vulnerability index indicates that IC in HK is substantially vulnerable to disruptions, while production-based vulnerabilities have the highest impact. Top management attention is needed to address these CSCVs in IC in HK. Originality/value To the authors' knowledge, this is the first structured evaluation model that measures the vulnerability level of IC, providing useful insights to industry stakeholders for well-informed decision-making in achieving resilient, sustainable and performance-enhanced SCs.

[Preliminary study of the antibody level in confirmed patients with COVID-19 after discharge].

Objective: To analyze the antibody levels and dynamic changes in patients infected with 2019-novel coronavirus(2019-nCoV). Methods: The average age of 72 corona virus disease 2019 (COVID-19) patients was (45.53±16.74)years(median age:47 year), including (44.88±17.09) years(median age:46 year) for 38 males and (46.32±16.52)years (median age:46 year) for 34 females in Loudi City, Hunan Province. There is no significant difference in genders between the severe and mild groups (χ²=0.916, P>0.05). There is a significant difference in the age between the severe and mild groups (F=3.315, P<0.05). The blood samples of 72 discharged patients were collected and the consistence of IgM and IgG antibodies were detected by chemiluminescence method. SPSS25.0 was used for gender, age, case type and antibody analysis of variance, χ2 test and other analysis. Results: The average time of the serum samples collection of 72 patients was (34.89±9.02)days (median time: 34 days) from onset of COVID-19, and (14.53±8.35) days (median time: 14 days) from discharge. The positive rate of IgM or IgG was 97.22% (70/72), and the positive rate of IgM and IgG was 48.61% (35/72) and 97.22% (70/72) respectively. Serum COVID-19 antibodies were detected in 72 patients from 1st to 40th days after discharge. The average concentration of IgM in 1-7 days, 8-14 days, 15-21 days, 22-28 days, above 29 days were 21.91(7.07-52.84)AU/ml, 14.16(6.19-32.88)AU/ml, 11.36(6.65-42.15)AU/ml, 8.15(3.66-30.12)AU/ml, 2.98(0.46-6.37)AU/ml. There was no significant difference in the time of IgM antibody concentration (H= 8.439, P>0.05). The average concentrations of IgG in 1-7 days, 8-14 days, 15-21 days, 22-28 days, 29 days and above were 169.90 (92.06-190.91) AU/ml, 163.89 (91.19-208.02) AU/ml, 173.31 (95.06-191.28) AU/ml, 122.84 (103.19-188.34) AU/ml, 101.98 (43.75-175.30) AU/ml, respectively, (H=2.232, P>0.05). The IgM becomes negative after the 3rd week of discharge and decreases rapidly with time. The IgG concentration higher than IgM during the same period, and keep at high level without any change, and decrease in the fourth week. Among them, 5 cases developed "re-infection" within 1-3 weeks after discharge, and the rate of "re-infection" was 6.94% (5/72 cases). Conclusions: After the COVID-19 patients are discharged from the hospital, the level of antibodies produced varies greatly among individuals, but the overall changes in antibodies have a certain pattern. It is recommended to strengthen the antibody monitoring during hospitalization and after discharge from the hospital to reduce the "re-infection" rate and potential risk of infection.

Screening process and management strategy of COVID-19 for outpaitent and emergency department in children's hospital

Since the occurrence of coronavirus disease 2019 (COVID-19) in Wuhan, Hubei Province of China in December 2019, the epidemic has developed rapidly and has now spread to the whole country. The pediatric hospital affiliated to Fudan University, as a designated hospital for treating children with infectious diseases in Shanghai, must be responsible for the treatment in children. The standardized hospital outpatient screening process management can improve the efficiency of diagnosis and treatment, reduce nosocomial infection, and control the spread of the epidemic. In order to deal with the epidemic situation, we carefully studied a series of laws and regulations, as well as instructions documents issued by the National Health and Health Commission, we reviewed and referenced recently published domestic and foreign literature, we also combined with the characteristics of children's specialist hospital, then formulated this screening process and management strategy of COVID-19 in outpatient and emergency departments. © 2020, Editorial Department of Fudan University Journal of Medical Sciences. All right reserved.